ReviewJHEP reports : innovation in hepatology2019
Public health policies and alcohol-related liver disease.
Review in JHEP reports : innovation in hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Dietary Polyphenols fromNutrients · 2026Article
- Dissecting incidence and mortality inequalities of six types of liver diseases in 39 alcohol-dominant countries and 93 virus-dominant countries under the aging context: Insights from the Global Burden of Disease Study 2021.Translational oncology · 2026Article
- Public health strategies for hepatocellular carcinoma: from risk factors to prevention and control.Journal of liver cancer · 2025Article
- Key Transcription Factors: Avenue for Treating Alcoholic Liver Disease.Current medical science · 2025Review
- Global, regional, and national burden of atrial fibrillation/flutter attributable to metabolic, behavioral, and environmental risk factors, 1990-2021: a longitudinal observational study.Frontiers in nutrition · 2025Article
- Targeting gut health: Probiotics as promising therapeutics in alcohol-related liver disease management.AIMS microbiology · 2025Review
- Trends in alcohol use and alcoholic liver disease in South Korea: a nationwide cohort study.BMC public health · 2024Article
- Individuals' travel to alcohol outlets: The fallacy of the local bar.Drug and alcohol review · 2024Article
- Impact of metabolic risk factors on hepatic and cardiac outcomes in patients with alcohol- and non-alcohol-related fatty liver disease.JHEP reports : innovation in hepatology · 2023Article
- Lipidomic Analysis of Liver Lipid Droplets after Chronic Alcohol Consumption with and without Betaine Supplementation.Biology · 2023Article
- Alcohol-related medicosocial problems and liver disorders: Burden of alcoholic cirrhosis and hepatocellular carcinoma in Turkiye.Hepatology forum · 2023Review
- Article
- Can alcohol control policies reduce cirrhosis mortality? An interrupted time-series analysis in Lithuania.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Identification of Quantifiable Predictors of Relapse in Patients with Alcohol-Associated Liver Disease.Hepatology communications · 2021Article
- Contemporary Trends in Hospitalizations for Comorbid Chronic Liver Disease and Substance Use Disorders.Clinical and translational gastroenterology · 2021Article
- Epidemiological Realities of Alcoholic Liver Disease: Global Burden, Research Trends, and Therapeutic Promise.Gene expression · 2020Review
- Current Management of Alcohol-Associated Liver Disease.Gastroenterology & hepatology · 2020Article
- Alcohol-Related Liver Disease in Latin America: Local Solutions for a Global Problem.Clinical liver disease · 2020Review
- Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies.Clinical and molecular hepatology · 2020Review
- Embracing basic and clinical innovation in hepatology.JHEP reports : innovation in hepatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol-related liver disease (ALD) represents a major public health problem worldwide. According to the World Health Organization, the highest levels of per capita alcohol consumption are observed in countries of the European Region. Alcohol consumption is also alarmingly increasing in developing countries. ALD is one of the main contributors to the burden of alcohol-attributable deaths and disability. In the United States, severe forms of ALD such alcoholic hepatitis have increased in the last decade and in the United Kingdom, three-quarters of liver-related mortality results from alcohol consumption. Besides genetic factors, there is strong evidence that the amount of alcohol consumed plays a major role in the development of advanced ALD. Establishing effective public health policies is therefore mandatory to reduce the burden of ALD. Since the 90s, major public health institutions and governments have developed a variety of policies in order to reduce the harm caused by excessive drinking. These policies encompass multiple factors, from pricing and taxation to advertising regulation. Measures focused on taxation and price regulation have been shown to be the most effective at reducing alcohol-related mortality. However, there are few studies focused on the effect of public policies on ALD. This review article summarises the factors influencing ALD burden and the role of different public health policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.